144 results on '"Gomez-Reino, Juan J"'
Search Results
2. Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs
3. Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares
4. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis
5. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
6. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
7. Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain
8. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
9. New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history
10. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis
11. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
12. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis
13. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes
14. Predictors of treatment failure and mortality in native septic arthritis
15. Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review
16. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
17. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
18. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
19. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación
20. Adipokines as novel modulators of lipid metabolism
21. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
22. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
23. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
24. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis
25. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
26. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective
27. Reply
28. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
29. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
30. Association of anti–citrullinated vimentin and anti–citrullinated α-enolase antibodies with subsets of rheumatoid arthritis
31. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
32. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
33. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors
34. Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations
35. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
36. Association of Interferon Regulatory Factor 5 Haplotypes, Similar to That Found in Systemic Lupus Erythematosus, in a Large Subgroup of Patients With Rheumatoid Arthritis
37. Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis
38. Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes
39. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage
40. Polymorphism of the Interleukin-1 Receptor Antagonist Gene: A Factor in Susceptibility to Rheumatoid Arthritis in a Spanish Population
41. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor
42. Association of PDCD1 With Susceptibility to Systemic Lupus Erythematosus: Evidence of Population-Specific Effects
43. A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus
44. Differential contribution of HLA-DR, DQ, and TAP2 alleles to systemic lupus erythematosus susceptibility in Spanish patients: role of TAP2[black star]01 alleles in Ro autoantibody production
45. Rheumatology: Inflammation and HIV infection: a friendly connection
46. Cumulative Rate of Relapse of Lupus Nephritis after Successful Treatment with Cyclophosphamide
47. Abnormal Carnitine Distribution in the Muscles of Patients with Idiopathic Inflammatory Myopathy
48. Long-term therapy for rheumatoid arthritis
49. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients
50. Respiratory chain enzyme defects in patients with idiopathic inflammatory myopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.